Oncternal Therapeutics to Report Second Quarter 2019 Financial Results and Provide Business Update
August 01 2019 - 4:01PM
Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage
biotechnology company developing potential first-in-class product
candidates for cancers with critical unmet medical need, today
announced that it will report second quarter 2019 financial results
after the market closes on Thursday, August 8, 2019.
Oncternal’s management will host a webcast and conference call
at 2:00 p.m. PDT (5:00 p.m. EDT) to discuss the Company’s
financial results and provide a comprehensive business update.
A live webcast of the call will be available online via a link
from the investor relations page of the Company’s website
at www.oncternal.com, and the call will be archived there for
at least 30 days.
About Oncternal Therapeutics Oncternal
Therapeutics is a clinical-stage biopharmaceutical company focused
on developing a diverse pipeline of product candidates for the
treatment of cancers with critical unmet medical need. Oncternal
focuses drug development on promising, yet untapped biological
pathways implicated in cancer generation and progression.
Oncternal’s pipeline includes its lead clinical program,
cirmtuzumab, a monoclonal antibody designed to inhibit the ROR1
receptor that is being evaluated in a Phase 1/2 clinical trial in
combination with ibrutinib for the treatment of chronic lymphocytic
leukemia and mantle cell lymphoma, and TK-216, a
small-molecule compound that is designed to inhibit ETS-family
oncoproteins, which is being evaluated in a Phase 1 clinical trial
alone and in combination with vincristine as a treatment for Ewing
sarcoma, a rare pediatric cancer. In addition, Oncternal has
a CAR-T product candidate that targets ROR1, which is
currently in preclinical development as a potential treatment for
hematologic cancers and solid tumors. More information is available
at www.oncternal.com.
Oncternal Contacts:
Investors
Richard Vincent
858-434-1113
rvincent@oncternal.com
Media
Jason Spark
619-849-6005
jason@canalecomm.com
Oncternal Therapeutics (NASDAQ:ONCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oncternal Therapeutics (NASDAQ:ONCT)
Historical Stock Chart
From Sep 2023 to Sep 2024